See more : Daekyo Co., Ltd. (019685.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Praxis Precision Medicines, Inc. (PRAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Praxis Precision Medicines, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Renaissance Global Limited (RGL.BO) Income Statement Analysis – Financial Results
- Nature Home Holding Company Limited (2083.HK) Income Statement Analysis – Financial Results
- Broncus Holding Corporation (2216.HK) Income Statement Analysis – Financial Results
- Sikozy Realtors Limited (SIKOZY.BO) Income Statement Analysis – Financial Results
- Nordhealth AS (NORDH.OL) Income Statement Analysis – Financial Results
Praxis Precision Medicines, Inc. (PRAX)
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 2.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.17M | 1.59M | 746.00K | 679.00K | 1.00K |
| Gross Profit | 2.45M | -1.17M | -1.59M | -746.00K | -679.00K | -1.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 86.77M | 155.04M | 120.26M | 44.98M | 29.56M | 18.82M |
| General & Administrative | 42.05M | 59.95M | 47.08M | 16.99M | 6.23M | 3.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 42.05M | 59.95M | 47.08M | 16.99M | 6.23M | 3.90M |
| Other Expenses | 0.00 | 957.00K | 271.00K | 140.00K | 0.00 | -3.65M |
| Operating Expenses | 128.82M | 214.99M | 167.33M | 61.97M | 35.79M | 22.72M |
| Cost & Expenses | 128.82M | 214.99M | 167.33M | 61.97M | 35.79M | 22.72M |
| Interest Income | 3.10M | 0.00 | 271.00K | 140.00K | 193.00K | 92.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.00K |
| Depreciation & Amortization | 432.00K | 1.17M | 1.59M | 746.00K | 679.00K | 1.00K |
| EBITDA | -125.94M | -212.86M | -165.47M | -61.08M | -34.92M | -26.27M |
| EBITDA Ratio | -5,146.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -126.37M | -214.99M | -167.33M | -61.97M | -35.79M | -22.72M |
| Operating Income Ratio | -5,164.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.10M | 957.00K | 271.00K | 140.00K | 193.00K | -3.68M |
| Income Before Tax | -123.28M | -214.03M | -167.06M | -61.83M | -35.60M | -26.40M |
| Income Before Tax Ratio | -5,037.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -957.00K | -182.00K | -8.00K | -84.00K | 133.00K |
| Net Income | -123.28M | -213.07M | -166.88M | -61.82M | -35.51M | -26.54M |
| Net Income Ratio | -5,037.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -18.69 | -69.33 | -58.96 | -103.61 | -348.24 | -306.73 |
| EPS Diluted | -18.69 | -69.33 | -58.96 | -103.61 | -348.24 | -306.73 |
| Weighted Avg Shares Out | 6.59M | 3.07M | 2.83M | 596.68K | 101.98K | 86.51K |
| Weighted Avg Shares Out (Dil) | 6.59M | 3.07M | 2.83M | 596.68K | 101.98K | 86.51K |
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript
Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
Source: https://incomestatements.info
Category: Stock Reports